Wednesday, May 29th, 2024

Today's Agenda

12:45 PM - 1:30 PM

JOHN F. KURTZKE MEMORIAL LECTURE
Beyond the Surface: Challenging Our Perceptions of Multiple Sclerosis
Faculty: Darin T. Okuda, MD, FAAN, FANA

1:45 PM - 3:45 PM

Clinical Course/Workshop
The Era of Too Many Choice: Starting and Switching MS Disease-Modifying Therapies
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
Application of History & Neurologic Examination for Accurate Expanded Disability Status Scale Score (EDSS) Assessment
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
Neuroanatomy for the MS Clinician: Insights and Clinical Pearls
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
Dilemmas in Long-Term DMT Management
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
MRI International Guidelines in Clinical Practice: Current and Up-and-Coming Approaches
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
The Life of a Woman With MS: A Case-Based Approach From Pregnancy and Beyond
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
Understanding Fatigue and Its Clinical Management
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
Optimizing Care in MS
Various Faculty

1:45 PM - 3:45 PM

Clinical Course/Workshop
Comorbidity Management Among People With Multiple Sclerosis: The Role of Registered Dietitian Nutritionists
Various Faculty

3:30 PM - 8:00 PM

EXHIBIT HALL OPEN

5:30 PM - 7:30 PM

EXHIBIT HALL

Opening Reception in Exhibit Hall

CMSC Highlights from Wednesday, May 29th, 2024

Expert Panel Offers Pointers for Managing MS During Pregnancy

May 30th 2024

MS does not carry an increased risk of high-risk pregnancy, but many clinicians are unclear about best practices for managing these patients.

In Multiple Sclerosis, There’s More to MRI Than Meets the Eye

May 30th 2024

CMSC Kurtzke Lecturer Darin Okuda, MD, demonstrates innovative ways to rethink MRI use in MS.

MAGNIFY-MS Analysis Further Demonstrates Cladribine’s Direct Impact on Central Nervous System in MS

May 29th 2024

Over a 24-month treatment period, patients on cladribine demonstrated no axonal loss evident on OCT, with reductions in cerebrospinal fluid neurofilament light and impacts on oligoclonal bands.

Margaret Fearey, Paige Greenawalt, Andrew J. Bouley, Joshua D. Katz

Premedication Regimen of Cetirizine, Dexamethasone, and Famotidine Prior to Ocrelizumab Leads to Less Sedation Issues, Study Shows

May 29th 2024

Nearly half of patients on diphenhydramine, dexamethasone, and famotidine experienced moderate to severe decreased alertness vs only 12.9% of those on cetirizine, dexamethasone, and famotidine.

Pregnancy and Infant Outcomes Remain Unchanged With Multiple Sclerosis Therapy Ocrelizumab

May 29th 2024

Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.